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A B S T R A C T 
Objective: To analyze the effect of curcumin in VEGF expression on Rattus norvegicus 
cervical cancer cell xenograft model. 
Methods: An experimental study with randomized post test only control group design. 
The subjects were Rattus norvegicus (Sprague Dawley), inoculated with He-la cervical 
cancer cells from American Type Culture Collection (ATCC) processed in stem cell 
laboratory Institute of Tropical Disease (ITD) Airlangga University. 5x10
6
 of He-La cells 
were injected subcutaneously in dorsal flank area of Rattus norvegicus. After 30 days of 
observation we performed histopathological examination of xenograft tissue and 
randomized into 2 groups which were given curcumin orally 1000 mg/kg (curcumin 
group) vs. no therapy (control group). After another 30 days the xenograft tissue was 
dissected and underwent immunochemistry examination for VEGF expression. 
Results: 32 samples of Rattus norvegicus were divided into 2 groups, In curcumin group 
the VEGF median expression was 2,2 (0,3-7,6) and in control group the VEGF median 
expression was 6,6 (1,2-12). There was a statistically significant difference with p value 
=0,009 with Mann Whitney test (p<0,05). 
Conclusion: VEGF expression in Rattus norvegicus xenograft model of cervical cancer 
was suppressed by giving Curcumin 1000 mg/kgBB orally. 
 
INTRODUCTION 
 
Cervical cancer is still a serious health problem 
worldwide, and the third major cancer death in the less 
developed countries (1). Most cervical cancer patients 
came already in advanced stage due to the lack of 
screening programs (2). In advanced cervical cancer, the 
only therapeutic option is chemoradiaton. However, 30-
40% of patients do not respond well to radiotherapy. 
Furthermore, chemotherapy does not provide 
maximum benefits due to side effects, toxicity and high 
resistance profile (3). Like other cancer, in the cervical 
cancer pathophysiology, if cancer has already reach 
certain size, it needs a vascular remodeling to ensure 
blood supply for tumor growth (6). 
Studies in cervical cancer therapy found anti-
angiogenic agents, bevacizumab, imatinib, andsunitinib 
effectively suppressed cervical cancer growth. However, 
the availability of these anti-angiogenic drugs is lacking 
due to high prices. Hence, there is chance to find and 
utilize other various phytopharmaca agents that have 
anti-cancer effects. 
Curcumin, is one of the natural ingredients from 
turmeric extract (Curcuma longa), is a type of tubers 
that are easily found, especially in Asian countries. 
Several previous studies had proven the biological and 
pharmacological effects of curcumin, including anti-
inflammatory, anti-oxidant, anti-artritic, anti-cancer, 
hepato-protective, anti-depressant, cardio-protective, 
anti-diabetic, immunomodulator, anti-Alzheimer's and 
analgesic. The benefits of curcumin as an anti-cancer 
have been widely proven, both in-vitro and in-vivo 
studies, including breast cancer, pancreatic cancer, 
cervical cancer and colon cancer. Curcumin works 
through various cellular pathways that suppress cancer 
growth (4). But the effect of curcumin on cervical cancer 
through the angiogenesis pathway has not been widely 
proven in-vivo. 
 
METHODS 
 
This is an experimental analytic study with a 
randomized post-test only control group design. The 
subjects of the study were Rattus norvegicus Sprague 
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Dawley strain that had been inoculated by He-La 
cervical cancer cells (American Type Culture Collection 
(ATCC) from the stem cell laboratory of the Institute of 
Tropical Disease (ITD), Airlangga University. 
A total of 5x106 he-La cells were injected 
subcutaneously in the dorsal flank area. After 30 days 
observation, histopathology examination was carried 
out to identify xenograft tissue. Randomization was 
done and we divided the subjects into two groups: the 
treatment group which received oral curcumin 1000 mg 
/ kg body weight, using curcumin for synthesis from  
Merck-Schuchardt, Germany with ingredients of 
curcumin 90%, and control group which did not get any 
therapy. 
After 30 days of curcumin treatment, xenograft 
tissue was dissected, and underwent 
immunohistochemical examination of VEGF expression. 
VEGF expression from each sample was assessed semi-
quantitatively according to the modified Remmele 
method, which is the multiplication result from 
immunoreactive cells with color intensity score on 
immunoreactive cells. Data for each sample was the 
average IRS value observed in 10 different field of view 
at 100x and 400x magnification. The calcutation of VEGF 
data was analyzed with Mann-Whitney test. 
This research was carried out in animal and 
pathology laboratory, Faculty of Veterinary Medicine, 
Airlangga University, from January to March 2018 after 
obtaining ethical clearance from the Commission for 
Research Ethics, Faculty of Veterinary Medicine, 
AIrlangga University No. 2.KE.049.03.2018 
 
RESULTS  
 
Rattus norvegicus were injected subcutaneously with 
5x106 cervical cancer He-La cells in the dorsal flank area, 
with cyclosporine injected as immunosuppressant. After 
a 30-day observation, xenograft tissue was identified 
with histopathology examination. Randomization was 
carried out, 32 samples were divided into 2 groups, 16 
samples in each group. In the treatment group curcumin 
1000 mg/kg/day was given orally, while in the control 
group no curcumin was given. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. He-La cells from ATCC (American Type Culture 
Collection) 
After 30 days of treatment, xenograft tissue 
dissection was performed and immunohistochemical 
examination was performed to quantify VEGF 
expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Xenograft tissue in the dorsal flank area of Rattus 
norvegicus. 
 
From the immunohistochemical examination, we 
obtained an overview of VEGF expression in the control 
and treatment groups (Figure 3 and Figure 4), with data 
analysis (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overview of VEGF expression in the control group 
showing chromogen brown color in the vascular endothelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Overview of VEGF expression in the curcumin group 
showed no brown chromogen in the vascular endothelium 
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Table 1. Comparison of VEGF expression in the control and 
curcumin group (Total sample =32) 
 
Group 
VEGF Expression  
Median Min. Max.  
Control (N=16) 6,60 1,2 12 P=0,009
* 
Curcumin (N=16) 2,20 0,3 7,6  
* Mann Whitney test 
 
 
Figure 5. Box plot median VEGF expression in the control and 
curcumin groups. 
 
DISCUSSION 
 
Management option for early stage cervical cancer is 
surgery, with a 5-year survival rate of 85 to 95%, 
whereas in the advanced stages, chemoradiation is a 
therapeutic option. Most cervical cancer patients came 
already in advanced stage due to the lack of screening 
programs. In advanced stage of cervical cancer, the 
main therapeutic options are radiation and 
chemotherapy. However, 30-40% of patients do not 
respond well to radiotherapy. The limitation of radiation 
facilities also causes the lengthening of the therapy 
duration which has an effect on increasing the 
recurrence rate and decreasing survival rate. 
Chemotherapy also does not provide maximum benefits 
due to side effects, toxicity, and high resistance (5). 
The development of medical science in finding 
cervical cancer therapy then leads to development of 
novel anti-angiogenic agents, such as bevacizumab, 
sunitinib, pazopanib and imatinib. In the GOG 240 study, 
bevacizumab significantly improves overall survival 
when combined with chemotherapy in patients with 
recurrent or persistent and metastatic cervical cancer. 
Inhibition of VEGF by bevacizumab results in 
disruption of the angiogenesis process wherein the 
cervical cancer, the process of angiogenesis occurs very 
active. The angiogenesis is the target of further anti-
cancer research, because angiogenesis is a very 
important factor in tumor growth, which when the 
tumor has grown to a certain size, the tumor requires a 
new blood vessel (6). 
Angiogenesis is the process by which new blood 
vessels are formed from vascular beds that already 
existed. Angiogenesis is an important process for tumor 
growth from localized small tumors to large tumors that 
have metastatic ability. When tumor growth reaches a 
size of + 1-2 mm in diameter or with a number of cells 
around 106 cells, the tumor requires remodeling and 
vascular growth, in addition to providing sufficient 
blood flow and also increases the chance of the tumor 
metastasis hematogenously (7). 
VEGF induces angiogenesis through direct effects on 
endothelial cells. In vitro studies showed microvascular 
growth of endothelial cells on the surface of 3-
dimensional collagen gels and VEGF was shown to 
induce cells to invade the underlying matrix and form a 
capillary-like tube structure. VEGF also produces a non-
mitogenic response by vascular endothelial cells. 
Endothelial cells in newly formed blood vessels undergo 
apoptosis with no signal to survive. By inducing anti-
apoptotic signals, VEGF is important for maintaining 
immature vascular viability (8). 
There is in-vivo evidence that VEGF can rapidly 
increase vascular permeability which results in leakage 
of plasma proteins and extravascular matrix, which 
further improves the environment that suitable for 
endothelial cell growth. In addition, increased vascular 
permeability will also increase interstitial pressure. 
Finally VEGF will induce chemotaxis, and expression of 
plasminogen activator and collagen in endothelial cells 
(9). 
VEGF is a key mediator of angiogenesis because it 
facilitates growth and remodeling processes of blood 
vessel, and provides mitogenic stimulation and survival 
for endothelial cells. VEGF also affects the immune 
system through several pathways. Experimental studies 
had shown that VEGF directly affects T-cells from early 
progenitor cells in the hematopoeiesis process and 
produces dendritic cells that are not functioning 
effectively (10). In addition, VEGF has been shown to 
have a mobilizing effect on endothelial precursor cells 
circulating in the vascular and hematopoietic stem cells, 
through mediation of monocyte migration (11). 
In this study, xenograft was performed using He-La 
cervical cancer cells. Several types of cervical cancer cell 
cultures that are widely used in research include He-La 
cells, Ca-Ski cells, and Si-Ha cells. He-la cell culture is the 
first cell culture, permanent and most widely used. This 
culture comes from cervical cancer cells taken on 
February 8, 1951 in patients with Henrietta Lacks, who 
later died of cancer. The xenograft model using He-la 
cells was first introduced in 1980 by Hisashi (7). 
Curcumin, an active phytochemical extraction 
ingredient from turmeric (Curcuma longa sp.), an Indian 
native spice plant which was first discovered in 1815 by 
Vo-gel and Pelletier. The chemical structure of curcumin 
Group 
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as diferuloylmethane was discovered by Milobedzka et 
al (1910). Since then, this polyphenol has been widely 
studied for its biochemical effects for medicinal 
purposes. 
Turmeric is widely processed by biotechnology 
companies, making it commercially available. Turmeric 
is generally safe for consumption, and has been 
recognized as Generally Recognized as Safe (GRAS) by 
the FDA. Chemical analysis of turmeric contains protein 
(6.3%), fat (5.1%), minerals (3.5%) carbohydrates 
(69.4%) and moisturizers (13.1%). Essential oils (5.8%) 
obtained from heating turmeric contained phellandrene 
(1%), sabinene (0.6%), cineol (1%), borneol (0.5%), 
zingiberene (25%), sesquiterpines( 53%), and curcumin 
(3-6%). The chemical formula of curcumin is C21H2006 
with chemical structure [1,7-bis- (4'-hydroxy-3'-
methoxyphenyl) hepta-1,6-diena-3,5-dion]. Curcumin is 
insoluble at neutral and acidic pH but can dissolve in 
methanol, ethanol, dimethylsulfoxide, and acetone. 
Some researchers have proven the sensitivity of 
curcumin to light so that materials containing curcumin 
are recommended to be protected from light (12). 
There had been many studies stated that curcumin is 
effective and safe. In experimental animals, oral 
administration of curcumin can reach serum and 
plasma. In humans, 3.6 g of oral curcumin were found to 
produce plasma curcumin 11.1 nmol / L after 1 hour 
consumption. To improve the low bioavailability of this 
curcumin several strategies were studied, among 
others, by changing the route of administration, 
medium used, conjugation and modification of 
curcumin such as nanocurcumin, liposome encapsulated 
curcumin, silica coated curcumin, and so on. The 
administration of curcumin with piperine is also a way 
to inhibit the rapid metabolism of curcumin (13). 
In clinical trials on colon cancer patients, 
administration of curcumin orally up to 8 g / kg / day 
was found to be safe and did not cause toxicity (8), 
while experiments in mice with 1000-1500 mg / kg body 
weight curcumin for 30 days had suppressed effect in 
VEGF, and inhibits the process of angiogenesis (14). 
Anti-cancer activity of curcumin was first proven 
both in vitro and in vivo by Kuttan et al in 1980 (15). In 
1995, it was found that curcumin increased anti-
inflammatory activity by suppressing the 
proinflammatory transcription factor nuclear factor (NF) 
-κB anti-potency curcumin cancer works by modulation 
of several cell signaling pathways including transcription 
factors, inflammatory cytokines, enzymes, kinases, 
growth factors, receptors, and various other proteins. 
Furthermore, curcumin also effectively regulates tumor 
cell growth through modulation of many cell signaling 
pathways and potentiates the effects of chemotherapy 
and radiation agents. Curcumin can interact with most 
targets stimulated by FDA-approved drugs for cancer 
therapy (16). 
The potential benefits of curcumin as an anti-cancer 
agent have been investigated in various studies both 
pre-clinical and clinical studies. In-vitro research and 
pre-clinical experiments show that the anti-carcinogenic 
activity of curcumin to be very promising, with its 
activity as an anti-cancer that can affect various 
pathways. In colon cancer, a combination therapy of 
oxaliplatin, 5-FU and leucovorin given with curcumin at 
a dose of 5 grams per day provides a good anticancer 
effect without any side effects at 5 months after therapy 
(17). In clinical trials in pancreatic cancer patients with 
poor prognosis, administration of curcumin significantly 
increased tumor regression (73%) along with an 
increase of 3-25% cytokines in the blood (12). Curcumin 
also has anti-leukemic effects by decreasing Nitric oxide 
(NO) synthesis in patients with chronic myeloid 
leukemia (18). 
The role of curcumin as an anti-HPV and anti-cervical 
cancer had been widely proven. The synergistic effect of 
curcumin with chemotherapeutic agents in-vitro 
showed that combination curcumin with paclitaxel 
increased apoptosis in cervical cells infected with HPV 
compared to paclitaxel alone (19). While administration 
of curcumin along with cisplatin was found to increase 
cell sensitivity to cisplatin through suppression of 
multidrug resistance protein (MRP) and P-glycoprotein 
(Pgp) by curcumin (20). 
Curcumin has been shown to reduce cell viability at 
various levels of cervical cancer cells. The administration 
of curcumin in He-La cervical cell culture resulted in 
changes in cell morphology, namely cell shrinkage. 
Curcumin also limits the metastases of cervical cancer, 
as well as regulation of NF-kB and cyclooxygenase-2 
(COX-2) (22). 
The most widely used xenograft process is He-La 
cells in cervical cancer patients. HeLa cell culture or He-
La cell line is a continuous cell line derived from cervical 
cancer epithelial cells of a woman named Henrietta 
Lacks who died of cancer in 1951. He-La cells are quite 
safe and are commonly used for the benefit of cell 
culture. HeLa is immortal which can divide indefinitely 
as long as it fulfills the basic conditions for the cell to 
remain alive. New strains of He-La cells have been 
developed in various cell cultures, but all He-La cells 
come from the same breed. He-La cells are cervical 
cancer cells due to infection with Human Papillomavirus 
(HPV 18) so that they have different properties with 
normal cervical cells. He-La cells can grow aggressively 
in suitable culture media (23). 
Various researches had been done on cervical cancer 
using He-La cells before. Research with He-La cells in-
vitro showed that Curcuma longa extract caused 
morphological changes in cells characterized by 
diminishing cell size, loss of cytoplasmic processes so 
that cells were spherical, and lost contact with other 
cells which are characteristic of apoptosis in most He-La 
cells. The nucleus appears dark because of the increased 
absorption capacity of the haematoxylene substance. 
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Statistical analysis showed significant differences 
between positive and negative control groups with 
stimulation groups in the number of cells undergoing 
morphological changes towards apoptosis. It was 
concluded that Curcuma longa extract was able to 
induce changes in He-La cell morphology in the form of 
cell shrinkage (21). In this study no measurement of 
tumor volume was carried out because the tumor tissue 
produced was small with unclear limits. This could be 
due to the type of mouse model used or the insufficient 
observation time. Previous research using 'athymic 
C57BL / 6 nude mice' mice with the same He-La cell 
injection of 5x106, with a 30-day observation time, 
found a significant tumor growth of ± 1cm, and carried 
out a volume measurement using the formula (length × 
width2 × 0.52) (8).  
Animal models had been developed for research on 
cancer. Experimental animal models were used to find 
factors involved in the malignancy transformation, 
invasion and metastasis, and to evaluate the response 
to therapy. One of the most widely used models is the 
xenograft tumor model. In this model human-derived 
tumor cells were transplanted under the skin or in other 
organs where the tumor originated in 
immunocompromized mice to minimize the rejection 
response of human cells. The tumor will grow within 1-8 
weeks, depending on the number of cells injected or the 
size of the transplanted tumor, and then the response 
to therapy can be studied in vivo. Another type of 
experimental animal to study cancer is the genetically 
engineered mouse model (GEM). The genetic profile of 
these mice has been changed. Furthermore, the effects 
of gene change are studied for a long time and the 
therapeutic response to these tumors can be followed 
in vivo. Both xenograft and GEM have been used for 
decades to find out the factors that influence tumor 
growth (24). 
Arjomandnejad in 2014 also conducted a study using 
a xenograft model in female C57BL/6 mice with 5x106 
He-La cells for CK, vimentin, P53, CD34 and Ki-67 
examination. After a latency of about 1 week, tumors 
begin to form with histological features showing 
malignancy with hyperchromatin cells. It was concluded 
that the use of xenograft with He-La cells was 
representative for cancer research and opened up great 
opportunities for the development of research on novel 
therapies for cervical cancer (8). 
In this study, the results of VEGF expression in the 
curcumin group were lower than the control group with 
mean of 2,2 in the treatment group and 6,6 in the 
control group. For data analysis, Mann-Whitney test 
was tested, found significant differences in VEGF 
expression in the control group and curcumin group 
with a significance value of p = 0.009 (p <0.05). VEGF 
expression was found to have decreased in this study by 
giving oral curcumin at a dose of 1 g/kg BW/ day for 30 
days. Another study using Ca-Ski cervical cancer cell 
xenograft model showed high dose of curcumin (1000 
mg and 1500 mg / kg / day) inhibited tumor growth 
(36%) and angiogenesis with decrease in VEGF, COX-2 
and EGFR while administration 500 mg / kg BW/ day had 
not shown beneficial effect. (14). Therefore this study 
used curcumin 1000 mg / kg BW/ day orally for 30 days 
of administration. 
In cervical cancer, there is also an excessive 
inflammatory process like in other cancers. NF-kB is a 
transcription factor that is maintained in an inactive 
form and resides in the cytoplasm by binding to the IkBa 
subunit in normal cells. With phosphorylation or 
degradation of IkBa, they are released and translocated 
to the nucleus where they cause cell division. Activation 
of NF-kB is known to induce anti-apoptosis and pro-
metastatic molecules including COX-2, cyclin D1, 
angiogenic factors (VEGF), cell matrix proteolytic 
enzymes (MMP-2 and MMP-9), and antiapoptotic 
proteins (Bcl-2, c-IAP1, surviving, and XIAP). In addition 
to being influenced by the process of angiogenesis, 
tumor growth is also influenced by the balance between 
proapoptotic and anti apoptotic proteins. The limitation 
of this study is that we only analyzed VEGF expression, 
while the expression of pro-apoptotic proteins,anti-
apoptotic proteins, and also MVD measurement were 
not performed. 
Curcumin is shown to inhibit the carcinogenesis by 
suppressing pro-angiogenic mediators such as VEGF and 
fibroblast growth factor (FGF). The anti-angiogenic 
activity of curcumin basically begins with its inhibitory 
effect on NF-κB transcription. Curcumin then inhibits 
matrix metallopreotease, plasminogen acivator and cell 
adhesion molecules associated with inhibition of 
angiogenesis. The effect of curcumin on the entire 
process of angiogenesis shows the potential of curcumin 
as an anti-angiogenic therapy. 
Various mechanisms can regulate VEGF, the most 
important is hypoxia. Hypoxia inducible factor (HIF1) is 
the main mediator of the hypoxic response. VEGF 
expression in tumor cells is stimulated by hypoxia, 
oncogenes, and inactivation of tumor suppressor genes 
(p53) and by various cytokines such as COX-2. In this 
study the presence of HIF1 was not studied, but 
theoretically the presence of stimulated free radicals 
from He-La cell injection is most likely to increase HIF1. 
In oxygen-sufficient cells HIF1α is synthesized and 
degraded continuously, but in hypoxia the degradation 
is inhibited so that HIF1 α accumulates and polymerizes 
with HIF1 β then binds DNA and recruits co-activator, so 
that it can activate the transcription of the target gene. 
Thus HIF1, which regulates various coordinated genes, 
works on the process of angiogenesis. 
Previous research from Shan found that curcumin 
inhibits the synthesis of hypoxia-induced mRNA and 
secretion from VEGFA in GH3 cells and the culture of 
pituitary adenoma cells in humans supports the 
suppressive effect on neovascularization of pituitary 
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tumors (25). Several other cancer studies have also 
stated that curcumin suppresses VEGF expression in 
Ehrlich tumor ascites cells and NIH3T3 cells (26), in 
pancreatic tumors (16), and in ovarian cancer (27). 
Curcumin can reduce the concentration of VEGF, IL-
1β and IL-4 in patients with colorectal cancer, lung 
cancer, liver cancer and also obesity. Curcumin also 
decreases ROS, VEGF, and PDGF in patients with Age 
Related Macular Degeneration Retinal Pigment 
Epithelium (AMD-RPEs) (4). 
Inhibition of VEGF secretion is also an effective 
strategy to prevent the spread of breast cancer because 
VEGF is the most potent angiogenic factor, regulated by 
NF-κB. Curcumin can inhibit metastasis and the 
angiogenic pathway in breast cancer cells through 
modulation of NF-κB protein expression of signaling 
pathways associated with NF-κB including VEGF (28). 
Curcumin suppress VEGF through the NF-κB 
pathway. Activation of NF-kB will induce several anti-
apoptotic and pro-metastatic molecules including COX-2 
proinflammatory proteins, cyclin-D1 cell cycle regulator 
proteins, angiogenic factors (VEGF), cell matrix 
proteolytic enzymes (MMP-2 and MMP-9), ICAM cell 
adhesion molecules and antiapoptotic proteins (Bcl-2, c-
IAP1, surviving, and XIAP). Curcumin also acts as a 
chemopreventive and anti-inflammatory agent by 
reducing HPV carcinogenesis and reducing the 
deregulation of various regulatory biomolecules, 
signaling pathways, and proinflammatory mediators, 
and limiting cervical cancer cell metastases (4). 
Research on animals given curcumin at a dose of 1 g 
/ kg BW/ day had a suppressive effect on VEGF. Previous 
studies have shown that curcumin in mice will rapidly 
metabolized through conjugation and reduction hence 
low bioavailability. Whereas in humans, the 
pharmacokinetics of curcumin is inconclusive. Clinical 
research in patients with pre-malignant lesions from 
colorectal cancer given curcumin up to 8 g per day for 3 
months does not cause toxicity (29). 
Research has shown that oral administration of 
curcumin in pancreatic cancer patients is well tolerated, 
even with low absorption, showing good biological 
activity. Tumor regression (73%) was accompanied by a 
significant (4-35-fold) increase in the number of 
cytokines (IL-6, IL-8, IL-10) (30). 
Another study on prostate cancer patients, which 
curcumin were administered at a dose of 6 mg / day 
combined with Docetaxel chemotherapy, was well 
tolerated, no toxicity, and reduced PSA (Prostate 
Specific Antigen) in 59% of patients compared to 
chemotherapy alone (31). 
All previous studies have shown low bioavailability of 
curcumin orally administered. Therefore further 
research is needed to improve the bioavailability, one of 
which is the liposomal curcumin formula, and the 
incorporation of curcumin with other substances such 
as piperine to increase the absorption of curcumin. 
CONCLUSION 
 
From this study we concluded that the 
administration of 1000 mg /kgBW/day curcumin for 30 
days decreased VEGF expression in Rattus norvegicus 
cervical cancer xenograft model significantly with a p-
value of 0.009 (<0.05). Further research is needed on 
the comparison of vascular density with tumor size as a 
continuation of differences in VEGF expression as a 
marker of the angiogenesis process. 
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